In this CME activity, leading experts in multiple myeloma will review changes in the treatment paradigm, optimal patient selection for transplant, and data from recent clinical trials. They will also provide insight into new strategies for individualized management, the role of early versus late transplant, and how to incorporate novel therapies into clinical practice.
Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for hematologic malignancies such as multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Various changes in the field over the past decade, including the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and NHL, plus the addition of new stem cell mobilization techniques, have led to the need to reassess current stem cell mobilization strategies.
Hematopoietic cell transplantation has become a cornerstone in the management of patients with lymphoma. The use of autologous transplant in Hodgkin’s and non-Hodgkin’s lymphoma has significantly improved the survivals of patients with relapsed disease.